In the study, none of the 45 participants experienced severe reactions, but more than half reported minor side effects at the site of injection, according to the NIAID. The trial now includes 120 participants, but the new findings cover its first 45 participants, all between the ages of 18 and 55.
[vc_row][vc_column][us_carousel post_type="ids" ids="260184, 260250, 107361" orderby="post__in" items_quantity="3" items_layout="11024" columns="3" items_gap="5px" overriding_link="post" breakpoint_1_cols="4" breakpoint_2_cols="3" breakpoint_3_cols="2"][/vc_column][/vc_row]
{
"slotId": "7483666091",
"unitType": "in-article",
"pubId": "pub-9300059770542025"
}
